Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$1,913.13

12.41 (0.65%)

, INTC

Intel

$57.59

-1.135 (-1.93%)

12:57
04/25/19
04/25
12:57
04/25/19
12:57

Notable companies reporting after market close

Notable companies reporting after the market close, with earnings consensus, include Amazon (AMZN), consensus $4.72... Intel (INTC), consensus 87c... Starbucks (SBUX), consensus 56c... T-Mobile (TMUS), consensus 92c... Illumina (ILMN), consensus $1.36... Capital One (COF), consensus $2.71... Ford Motor (F), consensus 26c... Aflac (AFL), consensus $1.06... Fortive (FTV), consensus 69c... Discover Financial (DFS), consensus $2.02... Juniper Networks (JNPR), consensus 21c... Grubhub (GRUB), consensus 25c... Cypress Semiconductor (CY), consensus 24c... Mattel (MAT), consensus (56c).

AMZN

Amazon.com

$1,913.13

12.41 (0.65%)

INTC

Intel

$57.59

-1.135 (-1.93%)

SBUX

Starbucks

$76.94

0.52 (0.68%)

TMUS

T-Mobile

$73.07

-0.28 (-0.38%)

ILMN

Illumina

$317.24

2.8 (0.89%)

COF

Capital One

$88.37

0.58 (0.66%)

F

Ford

$9.45

-0.135 (-1.41%)

AFL

Aflac

$49.00

0.11 (0.22%)

FTV

Fortive

$88.23

-0.85 (-0.95%)

DFS

Discover

$77.47

0.42 (0.55%)

JNPR

Juniper

$28.42

-0.305 (-1.06%)

GRUB

GrubHub

$71.22

1.92 (2.77%)

CY

Cypress Semiconductor

$16.26

-0.31 (-1.87%)

MAT

Mattel

$12.31

-0.24 (-1.91%)

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 01

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 06

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 14

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 21

    May

  • 22

    May

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 12

    Jun

  • 24

    Jul

  • 06

    Aug

  • 03

    Sep

  • 23

    Oct

  • 13

    Nov

AMZN Amazon.com
$1,913.13

12.41 (0.65%)

04/25/19
OPCO
04/25/19
NO CHANGE
Target $26
OPCO
Outperform
Sprouts Farmers Market price target lowered to $26 from $31 at Oppenheimer
Oppenheimer analyst Rupesh Parikh lowered his price target for Sprouts Farmers Market (SFM) to $26 from $31 ahead of quarterly results. The analyst notes that after outperforming in 2018, shares have meaningfully trailed year to date, reflecting the combination of a challenging 2019 earnings backdrop, continued dire sentiment toward grocers, and more recently adverse competitive actions from Amazon (AMZN)/Whole Foods on the pricing front. Parikh reiterates an Outperform rating on Sprouts Farmers Market shares and would take advantage of any potential weakness.
04/25/19
BMOC
04/25/19
NO CHANGE
Target $1200
BMOC
Market Perform
Alphabet price target raised to $1,200 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Alphabet (GOOGL) to $1,200 from $1,100 ahead of its Q1 results, but warns that he anticipates operating margin contraction driven by "accelerated hiring for Google Cloud" and erosion from growth in lower-margin products, such as YouTube and hardware." The analyst is also keeping his Market Perform rating on Alphabet, saying that while the valuation on the stock looks "attractive", he also sees the rise of advertising business at Amazon (AMZN) as a threat.
04/25/19
WEDB
04/25/19
NO CHANGE
Target $155
WEDB
Outperform
Microsoft price target raised to $155 from $150 at Wedbush
Wedbush analyst Daniel Ives raised his price target for Microsoft (MSFT) to $155 from $150 as he sees March results as "another feather in the cap for Nadella in the company's quest to become a cloud behemoth," with Azure growing 73% year over year and continuing to gain share versus the likes of AWS and Amazon (AMZN). Ives is bullish on Microsoft into the rest of 2019/2020 given his thesis that Azure's cloud momentum is still in its early days of playing out with the company's massive installed base, Office 365 transition on consumer/enterprise providing growth tailwinds for the next 12-18 months at least, and newer integrated product initiatives around consumers and cloud services are still playing out. He reiterates an Outperform rating on the shares.
04/24/19
KEYB
04/24/19
NO CHANGE
Target $2100
KEYB
Overweight
2019 narrative will be Amazon unlocking 'pools of profitability,' says KeyBanc
KeyBanc analyst Edward Yruma believes that the narrative in 2019 will be Amazon unlocking "pools of profitability," and thinks the U.S. retail business will show continued paid unit growth deceleration against a backdrop of accelerating profitability. Revenue is likely to come at the mid- to higher-end of guidance given a strengthening U.S. consumer, he contends. For AWS, Yruma believes the business has now reached escape velocity at $30B-plus scale. He reiterates an Overweight rating and $2,100 price target on the shares.
INTC Intel
$57.59

-1.135 (-1.93%)

04/17/19
WELS
04/17/19
NO CHANGE
WELS
Market Perform
Intel exiting 5G smartphone modem business 'a positive,' says Wells Fargo
Wells Fargo analyst Aaron Rakers says that following the Apple (AAPL)-Qualcomm (QCOM) settlement announcement, Intel (INTC) announced its intention to exit the 5G smartphone modem business. The analyst views this as a positive for Intel. Rakers reiterates a Market Perform rating on Intel's shares.
04/18/19
ARGS
04/18/19
NO CHANGE
Target $225
ARGS
Buy
Apple to benefit from Qualcomm litigation settlement, says Argus
Argus analyst Jim Kelleher kept his Buy rating and $225 price target on Apple (AAPL), saying the company's "comprehensive legal settlement and new supply agreement with Qualcomm (QCOM)" should benefit the shares. The analyst notes that the decision to settle was driven by the realization that Apple may miss out on the 5G phone cycle upgrade, and the announcement by Intel (INTC) within hours of the settlement highlighted that the Street was more optimistic about its development of a viable 5G chip. Kelleher adds that the cost burden for Qualcomm chip and licensing is not "too severe", which he estimates to be below $25 on devices that may retail for over $1.1K. The analyst also notes that Apple stock remains "attractive compared to its historical valuations and to peer average multiples."
04/17/19
KEYB
04/17/19
NO CHANGE
KEYB
Sector Weight
Intel 5G modem challenges a key factor leading to Apple settlement, says KeyBanc
KeyBanc analyst John Vinh notes that Qualcomm (QCOM) and Apple (AAPL) announced an agreement to dismiss all legal proceedings between the two companies worldwide, and says he believes challenges at Intel (INTC) on its 5G modem were a key factor leading to the settlement. The analyst also thinks this settlement likely will lead to a Huawei settlement, which could add another 80c in EPS for Qualcomm. While Vinh views the settlement as encouraging and as removing a major overhang for Qualcomm, he remains Sector Weight as he believes the economic benefit from the Apple settlement is largely reflected in the stock.
04/17/19
BARD
04/17/19
NO CHANGE
Target $10
BARD
Outperform
Lattice competitive landscape unchanged by Intel deal, says Baird
Shares of Lattice Semiconductor are trading lower on potential concerns related to smartphone procurement dynamics and the competitive landscape, Baird analyst Tristan Gerra tells investors in a research note. The analyst notes, however, that Lattice is de-emphasizing the smartphone market and no longer has content in Apple's (AAPL) new iPhones. Further, Intel's (INTC) acquisition of Omnitek does not change Lattice's competitive landscape, says Gerra. The analyst has an Outperform rating on Lattice Semiconductor with a $10 price target. The stock in afternoon trading is down 5%, or 62c, to $12.43.
SBUX Starbucks
$76.94

0.52 (0.68%)

04/08/19
04/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Underweight from Neutral at JPMorgan with analyst Stephen Tusa saying with the stock up 38% year-to-date, many investors are underestimating the severity of the challenges and underlying risks at GE, while overestimating the value of "small positives." 2. Starbucks (SBUX) downgraded to Neutral from Buy at UBS with analyst Dennis Geiger saying the risk/reward on shares "appears balanced" with the stock up 55% since June. 3. Boeing (BA) downgraded to Neutral from Buy at BofA/Merrill with analyst Ronald Epstein citing the company's announcement that it will cut 737 production rates to 42 per month from 52 per month, which he takes to likely mean that the 737 delay could last longer than previously expected. 4. Micron (MU) downgraded to Market Perform from Outperform at Cowen with analyst Karl Ackerman saying his field work indicates Micron's profitability will decline again in calendar year 2020. 5. Roku (ROKU) downgraded to Sell from Neutral at Citi with analyst Mark May saying the stock is up 110% year-to-date and near all-time highs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
PIPR
04/10/19
NO CHANGE
Target $70
PIPR
Neutral
Starbucks price target raised to $70 from $60 at Piper Jaffray
Piper Jaffray analyst Nicole Miller Regan raised her price target for Starbucks to $70 from $60 and keeps a Neutral rating on the name following March channel checks. In March, our Starbucks checks were steady in the positive mid-single-digit range, Regan tells investors in a research note. She notes, however, that her Starbucks checks, on average, have been approximately 120 basis points below actual results over the last four quarters. As such, the analyst is maintaining her positive 3% fiscal Q2 same-store sales estimate for the Americas segment. Regan remains Neutral rated on Starbucks with an "incrementally positive bias." It appears the potential overhang related to sales momentum and/or operational execution in the Americas segment has been partially removed, says the analyst.
04/18/19
OPCO
04/18/19
NO CHANGE
Target $81
OPCO
Outperform
Starbucks price target raised to $81 from $72 at Oppenheimer
Oppenheimer analyst Brian Bittner raised his price target for Starbucks to $81 from $72 on valuation as he remains confident in drivers behind healthy same-store sales. Nonetheless, the analyst recognizes that multiple expansion is difficult to justify in near-term. Bittner reiterates an Outperform rating on the stock, particularly ahead of an accelerating earnings scenario he envisions in 2020.
04/18/19
JEFF
04/18/19
NO CHANGE
Target $89
JEFF
Buy
Starbucks price target raised to $89 from $76 at Jefferies
Jefferies analyst Andy Barish raised his price target for Starbucks to $89 from $76 and keeps a Buy rating on the shares. The stock closed yesterday at $75.12. Barish says that despite the emergence of "Third Wave" coffee competitors, his "data-driven overlap analysis" and various growth scenarios point to a limited impact on Starbucks' same-store-sales. The company's competitive advantages, namely its size, scale and technology, and its shift to more suburban growth should support its long-term targets, Barish tells investors in a research note. The analyst raised his fiscal 2019 U.S. same-store-sales estimate to 4% from 3.3% and sees visibility to consistent 3%-4% sales and unit growth in the U.S.
TMUS T-Mobile
$73.07

-0.28 (-0.38%)

04/17/19
GSCO
04/17/19
NO CHANGE
GSCO
Sprint, T-Mobile headlines positive for Dish, Intelsat, says Goldman Sachs
Goldman Sachs analyst Brett Feldman, while taking no view on the outcome of the proposed merger between Sprint (S) and T-Mobile (TMUS), laid out his thoughts for other industry participants following the Wall Street Journal's report that the Department of Justice is unlikely to approve the deal as currently structured. The analyst believes investors will initially see the headlines as negative for the other major wireless carriers, namely AT&T (T) and Verizon (VZ), since they "create uncertainty over long-term industry structure." Further, investors will initially see these headlines as a slight positive for tower operators American Tower (AMT), Crown Castle (CCI) and SBA Communications (SBAC) as they "imply less risk of material cell site decommissioning," Feldman told investors earlier in a research note. The analyst also thinks investors will view the Journal's report as positive for owners of excess spectrum such as Dish (DISH) and Intelsat (I) and a slight positive for cable operators like Altice USA (ATUS), Charter (CHTR) and Comcast (CMCSA).
02/28/19
02/28/19
DOWNGRADE

Perform
American Tower downgraded to Perform on valuation at Oppenheimer
As previously reported, Oppenheimer analyst Timothy Horan downgraded American Tower (AMT) to Perform from Outperform on valuation. The analyst notes that the stock is up 19.5% since his wireless tower outlook published in early October, while Crown Castle (CCI) is up only 7.5%. While Horan acknowledges that American Tower's fundamentals are strong and the company is well positioned for growth, he believes there are near-term concerns. India churn brings volatility into the model, rising rates are a risk, as is the Spring (S)/T-Mobile (TMUS) merger and forex, he contends.
04/15/19
04/15/19
DOWNGRADE
Target $196

Market Perform
American Tower downgraded to Market Perform on valuation at Wells Fargo
As previously reported, Wells Fargo analyst Jennifer Fritzsche downgraded American Tower (AMT) to Market Perform from Outperform, while raising her price target on the shares to $196 from $190. The analyst notes that the stock is up 25%-plus year to data. Furthermore, Fritzsche remains concerned about headwinds on the international side of its business as well as 2019 guidance, which likely will not fall into the normal "beat and raise" story it has seen in the past given somewhat of a holding pattern of spending by carriers in the U.S. Additionally, while the outcome of the looming Sprint (S)/T-Mobile (TMUS) merger could impact the group overall, American Tower's valuation could be more impacted given its strong performance year to date, she contends.
04/17/19
WELS
04/17/19
NO CHANGE
WELS
Wells Fargo remains at 60% probability T-Mobile, Sprint deal gets approved
Wells Fargo analyst Jennifer Fritzsche notes that the Wall Street Journal reported DoJ staff expressed concerns about the Sprint (S)/T-Mobile (TMUS) merger at a meeting earlier this month as it would present a ''threat to competition." The analyst remains at a 60% of probability the deal gets approved, and does not see this report at new news. While Sprint's road is much more unknown in the event of no merger, in either scenario Fritzsche continues to favor T-Mobile's shares.
ILMN Illumina
$317.24

2.8 (0.89%)

04/23/19
ADAM
04/23/19
NO CHANGE
Target $360
ADAM
Buy
Illumina's setup into Q1 'favorable,' says Canaccord
Canaccord analyst Mark Massaro tells investors in a research note that he continues to like Illumina, despite the fact that the company expects growth to be more back-end loaded this year. He thinks the setup into Q1 is favorable as he believes Q1 and Q2 consensus revenue and earnings estimates are "reasonable." He maintains a Buy rating and $360 price target ahead of the company's Q1 report on Thursday after the close.
04/05/19
PIPR
04/05/19
NO CHANGE
Target $384
PIPR
Overweight
Piper confident into Illumina's Q1 report following channel checks
Piper Jaffray analyst William Quirk says his Q4 channel checks point toward in-line NovaSeq placements. However, large scale projects "continue to make headlines" and the analyst looks for these projects to drive "upside earlier-than expected." Further, his checks also showed some early adoption of the S-Prime chip. Quirk found 33 NovaSeqs in Q4, which suggests Illumina likely placed 66 in the quarter, in line with his 65 estimate. The analyst keeps an Overweight rating on the shares with a $384 price target and is confident heading into the Q1 report.
04/02/19
SPHN
04/02/19
DOWNGRADE
Target $8
SPHN
Equal Weight
Pacific Biosciences downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Drew Jones downgraded Pacific Biosciences of California (PACB) to Equal Weight from Overweight while raising his price target for the shares to $8 from $4.50. The shares are within 10% of the looming purchase price by Illumina (ILMN), Jones tells investors in a research note. He believes all public commentary suggests the deal remains on track to close in mid-2019.
04/02/19
OTRG
04/02/19
DOWNGRADE
OTRG
Mixed
Illumina downgraded to Mixed from Positive at OTR Global
COF Capital One
$88.37

0.58 (0.66%)

02/26/19
02/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/11/19
KEYB
02/11/19
NO CHANGE
Target $216
KEYB
Overweight
Workday price target raised to $216 from $179 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for Workday (WDAY) to $216 from $179 on improving cloud growth prospects. The analyst notes that analysis of Key First Look Data: Jobs has exposed an unannounced F50 HCM win at UPS (UPS) that began hiring for the global HR transformation team in January. The data also exposed unannounced F100 HCM wins at Comcast (CMCSA; CMCSK), CapitalOne (COF), and Centene (CNC), although job dates suggest these deals may have closed in the October quarter. The January data also exposed a new cloud financials win at Adecco (AHEXY), Bracelin adds. The analyst reiterates an Overweight rating on Workday's shares.
02/05/19
NOMU
02/05/19
NO CHANGE
Target $35
NOMU
Buy
Nomura tells investors to 'rethink their cautiousness' on Synchrony
Nomura Instinet analyst Bill Carcache raised his price target for Synchrony Financial (SYF) to $35 from $33 and reiterates a Buy rating on the shares. Although the short case on Synchrony "died last quarter" as renewals quelled fears around additional partnership losses and the announced sale of the Walmart (WMT) portfolio eradicated skepticism over whether Capital One (COF) would be a buyer, many investors are reluctant to get more bullish amid a perceived lack of incremental demand for Synchrony late cycle, Carcache tells investors in a research note titled ""Time to Get in Front of SYF as It Prepares to Take Down ~20% of Its Float; Raising TP to $35." While understanding the concerns, the analyst says it is "time for those on the sidelines to rethink their cautiousness." With over $4B to spend and a "laser focus" on mitigating the loss of Walmart, the analyst views Synchrony as a "deep pocketed incremental buyer that intends to reduce its float by ~20%."
02/26/19
SDLR
02/26/19
UPGRADE
Target $33
SDLR
Buy
Sandler O'Neill upgrades Ally Financial to Buy, says valuation premium warranted
As previously reported, Sandler O'Neill analyst Christopher Donat upgraded Ally Financial (ALLY) to Buy from Hold, stating that he believe Ally's (ALLY) near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. He thinks Ally deserves a slight premium to these specialty finance peers and raised his price target on Ally shares to $33 from $29 while maintaining his 2019 and 2020 EPS estimates.
F Ford
$9.45

-0.135 (-1.41%)

04/24/19
RBCM
04/24/19
NO CHANGE
RBCM
Strategic logic of Ford investment in Rivian 'solid,' says RBC Capital
RBC Capital notes that Ford and Rivian announced a strategic partnership whereby Ford will invest $500M minority equity investment and will develop an all-new BEV for its portfolio using Rivian's flexible skateboard architecture. The firm believes the strategic logic of the investment is "solid" from both sides, and accelerates Ford's ability to bring another BEV to market quicker and at lower cost versus an internally developed platform. Additionally, Ford gains knowledge about areas like batteries and electrical architecture, while Rivian gets and knowledge about scale manufacturing, RBC Capital adds.
04/23/19
PIPR
04/23/19
NO CHANGE
PIPR
Piper sees U.S. ride-hailing market reaching $500B per year by 2040
Piper Jaffray expects the U.S. ride-hailing market will achieve annual revenue of $500B per year by 2040, analysts led by Alexander Potter tell investors in a research note. The firm, which utilized baseline data from the National Household Travel Survey, expects ride-hailing growth to continue, with around one-third of urban trips relying on shared third-party vehicles in 2040. This compares to a baseline of only 1.4% in 2017, and equates to a 20-year annual growth rate of ~14%, the analysts contend. Of the stocks with exposure to this trend, Piper prefers Lyft (LYFT), General Motors (GM) and NXP Semiconductors (NXPI). Other covered companies also warrant mention, including Apple (AAPL), Amazon.com (AMZN), Aptiv (APTV), Ford (F), Nvidia (NVDA), and Tesla (TSLA), says Piper.
04/05/19
NOMU
04/05/19
DOWNGRADE
Target $7.5
NOMU
Reduce
Ford downgraded to Reduce on Europe challenges at Nomura Instinet
Nomura Instinet analyst Anindya Das downgraded Ford to Reduce from Neutral after lowering his volume forecast for Europe in March and revising his estimates for the extent of electrification required to meet the EU's upcoming emissions standards. Ford's higher share of the U.K. auto market compared to the rest of Europe makes it more susceptible to Brexit risks, Das added. He cut his price target on Ford shares to $7.50 from $8.20.
04/05/19
04/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Market Perform from Outperform at Wells Fargo with analyst Aaron Rakers saying the shares, after rallying 19% year-to-date, reflect a more balanced risk/reward. 2. Boston Beer (SAM) downgraded to Sell from Neutral at Goldman Sachs with analyst Judy Hong saying she sees headwinds in 2019 as competition intensifies and the company is "unlikely to repeat its innovation success again this year." 3. Ford (F) downgraded to Reduce from Neutral at Nomura Instinet with analyst Anindya Das saying Ford's higher share of the U.K. auto market compared to the rest of Europe makes it more susceptible to Brexit risks. 4. Constellation Brands (STZ) downgraded to Hold from Buy at Deutsche Bank. 5. International Paper (IP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Paul Quinn saying while International Paper is a "great company," investors have increased scrutiny on the containerboard market due to the "softening demand and fears of incremental capacity coming online" as year-to-date shipment growth slowed to 0.8% from 1.5% in 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AFL Aflac
$49.00

0.11 (0.22%)

12/31/18
ARGS
12/31/18
UPGRADE
Target $39
ARGS
Buy
Sun Life Financial upgraded to Buy at Argus on valuation
Argus analyst Jacob Kilstein upgraded Sun Life Financial (SLF) to Buy from Hold with a price target of $39, saying the company's valuation has become attractive after an 18% decline in the stock price since his last published report. The analyst cites Sun Life Financial's consistently strong earnings and above peer average ROE, along with some of its recent "small acquisitions" that should boost its earnings. Kilstein adds that his price target on the stock implies a forward earnings multiple of 10.5-times, which is still below the peer average of 11.7% valuation seen in the likes of Aflac (AFL) and Primerica (PRI).
01/02/19
JPMS
01/02/19
DOWNGRADE
Target $51
JPMS
Neutral
Aflac downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jimmy Bhullar downgraded Aflac to Neutral with an unchanged price target of $51. The analyst forecasts insurers to generate "healthy" margins in their foreign businesses, especially in Japan, but he adds that "lackluster" sales and negative currency moves present headwinds. He points out that Aflac has the most exposure to international markets among the names he covers.
02/04/19
RHCO
02/04/19
NO CHANGE
Target $48
RHCO
Hold
Aflac price target raised to $48 from $44 at SunTrust
SunTrust analyst Mark Hughes raised his price target on Aflac to $48 after its Q4 earnings beat, also raising his FY19 EPS outlook by 10c to $4.20. The analyst cites the "continued strength in profitability within both Japanese and US operations and sustained share buybacks" for Aflac, but also sees its risks and rewards as "fairly balanced" at current levels, keeping a Hold rating on the shares.
10/03/18
JPMS
10/03/18
NO CHANGE
JPMS
JPMorgan sees attractive risk/rewards for life insurance stocks
Life insurance stocks offer attractive risk/reward profiles at current share levels, JPMorgan analyst Jimmy Bhullar tells investors in a research note. The analyst, who's been cautious on the sector for the past two years, says that while his fundamental view "remains mixed," the macro environment has improved, investor sentiment has become negative, and valuation levels are more reasonable following the group's significant underperformance. He maintains Overweight ratings on Aflac (AFL), Lincoln National (LNC), and Prudential (PRU) and reiterates his negative stance on Brighthouse Financial (BHF).
FTV Fortive
$88.23

-0.85 (-0.95%)

11/19/18
BMOC
11/19/18
NO CHANGE
Target $45
BMOC
Outperform
Altra Industrial Motion price target lowered to $45 from $47 at BMO Capital
BMO Capital analyst R. Scott Graham lowered his price target on Altra Industrial Motion (AIMC) to $45 after his meetings with its CEO and CFO to discuss the company's current operating environment, the integration of Fortive's (FTV) Automation and Specialty business, tariffs and leverage. The analyst maintains his Outperform rating based on the management's positive outlook, but attributes the price target change to expectations of reduced core productivity from the merger. Graham adds that he still views the Automation and Specialty combination positively, but also points to Altra Industrial's rising leverage after the deal.
12/18/18
MSCO
12/18/18
UPGRADE
Target $82
MSCO
Overweight
Fortive assumed at Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Joshua Pokrzywinski assumed coverage of Fortive with an Overweight rating, up from the firm's prior Equal Weight rating, stating that he believes its increased focus on software and recurring revenues should drive outperformance. He sees recent M&A transactions moving long-term growth closer to 4% and margins toward 23%, Pokrzywinski tells investors. He set an $82 price target on Fortive shares, down from the prior $84 target.
01/03/19
FBCO
01/03/19
NO CHANGE
Target $78
FBCO
Neutral
Fortive price target lowered to $78 from $86 at Credit Suisse
Credit Suisse analyst John Walsh lowered his price target for Fortive to $78 from $86 to reflect a 20bps reduction in global industrial production expectations, a 200bps reduction in energy capex driven by reduced E&P spending, and current FX rates. The analyst reiterates a Neutral rating on the shares.
12/18/18
12/18/18
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lionsgate (LGF.A, LGF.B, LGF) upgraded to Buy from Hold at Deutsche Bank. 2. Norfolk Southern (NSC) upgraded to Overweight from Neutral at JPMorgan with analyst Brian Ossenbeck saying he estimates $600M of potential productivity gains based on his analysis and points out that he has long favored Eastern rails as a region. 3. China Life Insurance (LFC) upgraded to Neutral from Sell at Goldman Sachs. 4. Ametek (AME) and Fortive (FTV) were assumed at Overweight from Equal Weight at Morgan Stanley. 5. Host Hotels (HST) upgraded to Outperform from In Line at Evercore ISI, while Public Storage (PSA) was upgraded to In Line from Underperform. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DFS Discover
$77.47

0.42 (0.55%)

03/06/19
MSCO
03/06/19
NO CHANGE
Target $91
MSCO
Overweight
Discover shares should be bought before April credit turn, says Morgan Stanley
Morgan Stanley analyst Betsy Graseck recommended buying Discover shares despite the fact that the stock has outperformed year-to-date, as she expects continued outperformance as credit quality starts to improve seasonally beginning in April. Noting that credit trends have been coming in better year-over-year for the past five quarters, Graseck raised her forward 2020 EPS estimates by 2% and increased her price target on Discover shares to $91 from $89 while keeping an Overweight rating on the stock.
04/16/19
JPMS
04/16/19
UPGRADE
Target $23
JPMS
Neutral
Santander Consumer upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Richard Shane upgraded Santander Consumer (SC) to Neutral from Underweight and raised his price target for the shares to $23 from $20. The analyst remains constructive on the U.S. consumer into the second half of 2019 as he believes "strong" labor markets and wage growth "provide a stable foundation for credit." Santander Consumer is positioned to announce a "significant" return of capital heading into the Q1 reporting season, Shane tells investors in a research note. Discover Financial (DFS) is the analyst's best idea in the group over the next 12 to 18 months.
JNPR Juniper
$28.42

-0.305 (-1.06%)

01/30/19
RBCM
01/30/19
NO CHANGE
Target $26
RBCM
Sector Perform
Juniper price target lowered to $26 from $29 at RBC Capital
RBC Capital analyst Mitch Steves lowered his price target on Juniper to $26 after its Q4 results and below-consensus FY19 guidance. The analyst notes that the company cited weaker Q1 cloud revenue, negative impact from the government shutdown, and a shift in its go-to-market strategy. Steves also keeps his Sector Perform rating on Juniper given its track record of "stable performance over the last four years", forecasting low single digit growth longer term on strength in the telecom, cable, and cloud provider market.
01/30/19
JPMS
01/30/19
NO CHANGE
Target $24
JPMS
Underweight
Juniper price target lowered to $24 from $26 at JPMorgan
JPMorgan analyst Samik Chatterjee lowered his price target for Juniper Networks to $24 from $26 and reiterates an Underweight rating on the shares following the company's Q4 results. The primary driver of the softer revenue outlook was the "familiar cloud driven headwind that has challenged Juniper's top-line growth throughout 2018," Chatterjee tells investors in a research note. He sees these cloud headwinds delaying Juniper's return to revenue growth.
01/30/19
01/30/19
DOWNGRADE
Target $25

Underperform
BofA double downgrades Juniper to Underperform on 'weak' fundamentals
As previously reported, BofA Merrill Lynch analyst Tal Liani double downgraded Juniper Networks to Underperform from Buy after the company reported "weak" Q4 results and guidance and management said the demand and pricing trends that are hurting them will likely not improve in the foreseeable future. The company's effort to penetrate cloud vendors with switches will require new products and may take time, Liani added. He lowered his estimates in the wake of the results and guidance and cut his price target on Juniper shares to $25 from $33.
01/30/19
WOLF
01/30/19
DOWNGRADE
WOLF
Peer Perform
Juniper downgraded to Peer Perform from Outperform at Wolfe Research
GRUB GrubHub
$71.22

1.92 (2.77%)

04/12/19
JEFF
04/12/19
NO CHANGE
Target $80
JEFF
Hold
Food delivery is not winner-take-all industry, says Jefferies
Jefferies analyst Brent Thill believes much of this information disclosed last night by Uber (UBER) regarding Uber Eats was already well understood by investors. Uber has been more transparent about the Eats business the last couple quarters, Thill tells investors in a research note. He points out that GrubHub (GRUB) shares are down 54% from their highs, which he believes is due to increased competition and disclosures from Uber and other larger players. Uber Eats is likely losing money while GrubHub has been profitable since its initial public offering, says Thill. Further, he believes that while the "rapid growth" of Eats creates a challenging competitive environment, third party food delivery is not a winner-take-all industry. The analyst, while acknowledging GrubHub's risk/reward is getting more attractive, keeps a Hold rating on the stock with an $80 price target. Thill continues to like Waitr Holdings (WTRH) and would be a buyer of the stock on the recent pullback.
04/17/19
CHLM
04/17/19
NO CHANGE
Target $100
CHLM
Buy
GrubHub price target lowered to $100 from $120 at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman lowered his price target for GrubHub to $100 from $120 as he believes growth in its restaurant network is beginning to slow. Nonetheless, Q1 results should be strong. He reiterates a Buy rating on the shares.
04/12/19
WEDB
04/12/19
NO CHANGE
Target $100
WEDB
Outperform
GrubHub price target lowered to $100 from $130 at Wedbush
Wedbush analyst Ygal Arounian lowered his price target for GrubHub (GRUB) to $100 from $130 but maintained an Outperform rating after Uber (UBER) released its S-1, which included data on its Uber Eats division, to better reflect the continued changes in competitive dynamics. In a research note to investors, Arounian says GrubHub investors were likely hoping for more clarity on Uber Eats' U.S. diners and gross food sales, but says take rates are "comparable but headed in different directions," with GrubHub's take rate on the rise and Uber Eats' take rate declining. He estimates Uber Eats' U.S. scale is where he previously expected and trails GrubHub.
04/03/19
04/03/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. GrubHub (GRUB) initiated with a Buy at BTIG. 2. AMD (AMD) and Intel (INTC) initiated with a Buy at Nomura Instinet, while Nvidia (NVDA) and Xilinx (XLNX) were initiated with a Neutral. 3. Futu (FHL) initiated with a Neutral at Goldman Sachs. 4. Square (SQ) initiated with a Market Perform at Bernstein. 5. DowDuPont (DWDP) and Dow Inc. (DOW) initiated with a Buy at UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CY Cypress Semiconductor
$16.26

-0.31 (-1.87%)

04/12/19
NEED
04/12/19
NO CHANGE
Target $20
NEED
Buy
Cypress Semiconductor price target raised to $20 from $16 at Needham
Needham analyst Rajvindra Gill raised his price target on Cypress Semiconductor to $20 and kept his Buy rating to reflect his "stronger conviction" for the company's margin profile and his favorable sales mix outlook. In spite of the 25% year-to-date rise, the analyst points to the stock trading near a multi-year price-to-earnings lows, along with the company's "defensible technological barriers in Wi-Fi/Bluetooth Low Energy, high-density NOR memory, and PSoC microcontroller." Gill further believes that Cypress Semi is well positioned in the Internet of Things, auto, and industrial industries experiencing secular growth.
03/28/19
MSCO
03/28/19
DOWNGRADE
Target $24.5
MSCO
Equal Weight
Quantenna Communications downgraded to Equal Weight at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach downgraded Quantenna Communications (QTNA) to Equal Weight from Overweight and raised his price target on the stock to $24.50 from $18.00 to reflect the company's agreement to be acquired by ON Semiconductor (ON). For ON, Hettenbach estimates a stock buyback would be "meaningfully more accretive over the intermediate term," stating that the company said they expect the deal to be around 5c accretive to EPS but using the same amount of cash to buy back stock at an average price of $22 could add 20c to 2020 EPS. The analyst, who sees other competitors - such as Cypress (CY), Microchip (MCHP) and Texas Instruments (TXN) - being "much better positioned" in low power WiFi, keeps an Underweight rating on ON Semiconductor shares.
03/14/19
MKMP
03/14/19
NO CHANGE
Target $18
MKMP
Buy
Cypress Semiconductor price target raised to $18 from $16 at MKM Partners
MKM Partners analyst Ruben Roy raised his price target on Cypress Semi to $18 and kept his Buy rating after its Analyst Day presentation yesterday. The analyst says the company's focus on Internet of Things and Automotive markets position it for above-market growth rates, with the management presentation offering a "good look into various examples and company specific differentiation" that should support its forecasts. Roy adds that the company's increase in longer-term gross margin forecasts and attractive valuation warrant a price target increase.
03/28/19
MSCO
03/28/19
NO CHANGE
MSCO
Infineon warning a 'reality check' for semiconductor group, says Morgan Stanley
Morgan Stanley analyst Craig Hettenbach noted that Infineon cut its FY19 revenue guidance by around 3.5% yesterday, citing elevated inventory in China autos and distribution broadly. Hettenbach calls the negative pre-announcement "an important reality check for semis" that calls into question recently building optimism for a second half rebound. Hettenbach maintains a Cautious view on Semis as a group and lists Sensata (ST), NXP Semiconductors (NXPI), TE Connectivity (TEL), Cypress Semiconductor (CY) and ON Semiconductor (ON) as stocks he covers that have meaningful exposure to autos.
MAT Mattel
$12.31

-0.24 (-1.91%)

10/26/18
JEFF
10/26/18
NO CHANGE
Target $13
JEFF
Hold
Jefferies says Mattel valuation 'still stretched,' cuts target to $13
At first glance, Mattel's earnings report "was in range," but unpacking the results uncovered a "more challenging set of facts" with sales down 10%, Jefferies analyst Stephanie Wissink tells investors in a post-earnings research note. She lowered her estimates for Mattel and dropped her price target for the shares to $13 from $14. The multiple at current share levels is " still stretched," says Wissink.
02/26/19
BMOC
02/26/19
NO CHANGE
Target $20
BMOC
Outperform
Mattel price target lowered to $20 from $23 at BMO Capital
BMO Capital analyst Gerrick Johnson lowered his price target on Mattel to $20 after attending the company's Toy Fair analyst event. The analyst states that while he is "encouraged" by its efforts to reposition business toward profitable growth, the turnaround involving "SKU rationalization,process improvement, cost reduction, and infrastructure investments" could take longer than he anticipated. Longer term, Johnson keeps his Outperform rating on Mattel and believes that the stock still has "value that will continue to be unlocked" amid the management's transformation efforts.
02/08/19
MKMP
02/08/19
NO CHANGE
Target $15
MKMP
Neutral
Mattel price target raised to $15 from $12 at MKM Partners
MKM Partners analyst Eric Handler raised his price target on Mattel to $15 after its Q4 results surprised to the upside. The analyst also keeps his Neutral rating, noting that while the cost cuts have contributed to the earnings beat, the "revenue turnaround is still a work in progress".
12/24/18
BMOC
12/24/18
NO CHANGE
Target $20
BMOC
Spin Master licensing deal with Warner negative for Mattel, says BMO Capital
BMO Capital analyst Gerrick Johnson says the Friday report of a DC superheroes licensing deal between Toys R Us Spin Master and Warner is a negative for Mattel. While the report has not been confirmed, the analyst believes that the business will be lost after 2019. Longer term, the analyst keeps his Outperform rating and $20 price target on Mattel and believes that its management "can facilitate needed changes in culture, product development, digital content, and partner relationships to drive sales and earnings growth."

TODAY'S FREE FLY STORIES

ESLT

Elbit Systems

$154.55

0.55 (0.36%)

13:41
06/16/19
06/16
13:41
06/16/19
13:41
Hot Stocks
Elbit Systems awarded $50M contract »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$176.09

-0.74 (-0.42%)

13:40
06/16/19
06/16
13:40
06/16/19
13:40
Hot Stocks
Amgen announces BLINCYTO five-year overall survival data »

Amgen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

SILK

Silk Road Medical

$44.80

-0.95 (-2.08%)

13:35
06/16/19
06/16
13:35
06/16/19
13:35
Hot Stocks
Silk Road Medical announces final results for ROADSTER-2 study »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 26

    Aug

EDIT

Editas Medicine

$21.72

-0.78 (-3.47%)

13:30
06/16/19
06/16
13:30
06/16/19
13:30
Hot Stocks
Editas presents pre-clinical data in Sickle Cell Disease, Beta-Thalassemia »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.90

-0.055 (-5.79%)

13:28
06/16/19
06/16
13:28
06/16/19
13:28
Hot Stocks
Sunesis announces preliminary data from Phase 1b/2 trial of Vecabrutinib »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

APLS

Apellis

$21.22

-0.14 (-0.66%)

13:23
06/16/19
06/16
13:23
06/16/19
13:23
Hot Stocks
Apellis presents data from ongoing Phase 2 PLAUDIT study of APL-2 »

Apellis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

FTSV

Forty Seven

$10.55

-0.02 (-0.19%)

13:16
06/16/19
06/16
13:16
06/16/19
13:16
Hot Stocks
Forty Seven announces data from Phase 1b/2 trial of 5F9 in combo with Rituximab »

Forty Seven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

13:06
06/16/19
06/16
13:06
06/16/19
13:06
Hot Stocks
AstraZeneca announces results from interim analysis of Phase 2 ASCEND trial »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

STRO

Sutro Biopharma

$11.17

-0.34 (-2.95%)

13:02
06/16/19
06/16
13:02
06/16/19
13:02
Hot Stocks
Sutro Biopharma announces interim Phase 1 safety data for STRO-001 »

Sutro Biopharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$90.65

-0.35 (-0.38%)

12:59
06/16/19
06/16
12:59
06/16/19
12:59
Hot Stocks
Blueprint Medicines presents updated EXPLORER trial data for Avapritinib »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

INCY

Incyte

$77.76

1.385 (1.81%)

12:52
06/16/19
06/16
12:52
06/16/19
12:52
Hot Stocks
Incyte announced results from Phase 2 study of Ruxolitinib cream in vitiligo »

Incyte announces 24-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/16/19
06/16
04:55
06/16/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

, GRUB

GrubHub

$70.15

-2.76 (-3.79%)

13:28
06/15/19
06/15
13:28
06/15/19
13:28
Periodicals
Amazon exit gives GrubHub stock boost, Barron's says »

Amazon (AMZN) is…

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

, CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

13:20
06/15/19
06/15
13:20
06/15/19
13:20
Periodicals
McKesson, Cardinal Health looking like bargains, Barron's says »

Investors have halved the…

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

RTN

Raytheon

$177.38

0.195 (0.11%)

, UTX

United Technologies

$125.30

0.45 (0.36%)

13:09
06/15/19
06/15
13:09
06/15/19
13:09
Periodicals
United Technologies, Raytheon stocks looking cheap, Barron's says »

Shares of United…

RTN

Raytheon

$177.38

0.195 (0.11%)

UTX

United Technologies

$125.30

0.45 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

, AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

13:04
06/15/19
06/15
13:04
06/15/19
13:04
Periodicals
Food fight extending well beyond restaurant delivery, Barron's says »

Amazon (AMZN) is quitting…

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

, GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

12:59
06/15/19
06/15
12:59
06/15/19
12:59
Periodicals
Facebook, JPMorgan chiefs among Best CEOs of 2019, Barron's says »

Separated into three…

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

FB

Facebook

$181.35

3.88 (2.19%)

MCD

McDonald's

$205.33

0.85 (0.42%)

JPM

JPMorgan

$109.84

0.26 (0.24%)

BAC

Bank of America

$28.03

0.09 (0.32%)

BLK

BlackRock

$446.96

-1.29 (-0.29%)

BX

Blackstone

$44.13

0.17 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

  • 27

    Oct

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

, AAPL

Apple

$192.84

-1.93 (-0.99%)

07:17
06/15/19
06/15
07:17
06/15/19
07:17
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

AAPL

Apple

$192.84

-1.93 (-0.99%)

HNHPF

Hon Hai Precision

$0.00

(0.00%)

UTX

United Technologies

$125.30

0.45 (0.36%)

RTN

Raytheon

$177.38

0.195 (0.11%)

CGC

Canopy Growth

$41.15

-0.64 (-1.53%)

TLRY

Tilray

$38.96

-1.78 (-4.37%)

APHA

Aphria

$6.80

-0.15 (-2.16%)

ACB

Aurora Cannabis

$7.56

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$15.43

-0.92 (-5.63%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.28

0.4201 (48.85%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

ZYNE

Zynerba

$13.03

-0.54 (-3.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 18

    Jun

  • 19

    Jun

  • 21

    Jun

  • 25

    Jun

  • 09

    Jul

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, ABMD

Abiomed

$250.96

-4.58 (-1.79%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
International League of Dermatological Societies to hold a conference »

24th World Congress of…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

ABMD

Abiomed

$250.96

-4.58 (-1.79%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

JNJ

Johnson & Johnson

$140.08

-0.63 (-0.45%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PG

Procter & Gamble

$111.20

0.28 (0.25%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

UL

Unilever; also tag UN

$62.61

-0.07 (-0.11%)

UN

Unilever; also tag UL

$61.30

-0.13 (-0.21%)

INCY

Incyte

$77.76

1.385 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 26

    Jun

  • 27

    Jun

  • 16

    Jul

  • 25

    Jul

  • 30

    Jul

  • 28

    Aug

  • 03

    Sep

  • 16

    Sep

  • 13

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

, GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Congress of Rheumatology to hold a conference »

EULAR 2019 will be held…

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

PFE

Pfizer

$42.75

0.24 (0.56%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

RHHBY

Roche

$0.00

(0.00%)

BIIB

Biogen

$227.67

-3.57 (-1.54%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

REGN

Regeneron

$305.19

-2.235 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 25

    Jul

  • 30

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jun

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ABT

Abbott

$82.25

-0.03 (-0.04%)

, AMGN

Amgen

$176.09

-0.74 (-0.42%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
Society for Vascular Surgery to hold annual meeting »

SVS Annual Meeting 2019…

ABT

Abbott

$82.25

-0.03 (-0.04%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

BSX

Boston Scientific

$40.41

-0.26 (-0.64%)

PFE

Pfizer

$42.75

0.24 (0.56%)

CRY

CryoLife

$29.13

-0.13 (-0.44%)

EW

Edwards Lifesciences

$184.00

-0.63 (-0.34%)

ELGX

Endologix

$7.61

0.2 (2.70%)

IAC

IAC

$228.41

-2.63 (-1.14%)

HCA

HCA Healthcare

$126.64

-0.76 (-0.60%)

LMAT

LeMaitre

$26.04

-0.44 (-1.66%)

ORGO

Organogenesis

$7.39

0.02 (0.27%)

OSIR

Osiris

$0.00

(0.00%)

PEN

Penumbra

$166.75

2.93 (1.79%)

SWAV

ShockWave Medical

$58.27

-0.99 (-1.67%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 26

    Jun

  • 09

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 16

    Sep

  • 25

    Sep

  • 13

    Nov

CNC

Centene

$53.52

-0.26 (-0.48%)

, WCG

WellCare

$287.16

0.145 (0.05%)

18:45
06/14/19
06/14
18:45
06/14/19
18:45
Hot Stocks
Centene CEO: Medicare for all will not work »

In an interview on…

CNC

Centene

$53.52

-0.26 (-0.48%)

WCG

WellCare

$287.16

0.145 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

HMC

Honda

$25.34

-0.405 (-1.57%)

18:24
06/14/19
06/14
18:24
06/14/19
18:24
Hot Stocks
Honda recalls all 2016-2019 model year Pioneer vehicles »

Honda is conducting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$111.28

1.42 (1.29%)

18:22
06/14/19
06/14
18:22
06/14/19
18:22
Hot Stocks
RH CEO: We think our stock is massively undervalued »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.